Nikotin in den unterschiedlichsten Darreichungsformen verringert bei verschiedenen Spezies im räumlichen Hinweisreizparadigma die Kosten invalider Hinweisreize. Welcher Teilprozess genau durch Nikotin beeinflusst wird, ist bislang nicht untersucht worden. Die gängige Interpretation ist, daß Nikotin das Loslösen von Aufmerksamkeit von einem bisher beachteten Ort erleichtert. In fünf Studien, drei elektrophysiologischen und zwei behavioralen wurden drei mögliche Mechanismen der Nikotinwirkung an Nichtrauchern untersucht. Experiment 1 und 2 gingen der Frage nach, ob Nikotin eine Modulation sensorischer gain Kontrolle bewirkt. Dazu wurden ereigniskorrelierte Potentiale (EKP) im Posner-Paradigma erhoben und die Wirkung von Nikotin auf die aufmerksamkeitsassoziierten Komponenten P1 und N1 betrachtet. Nikotin verringerte die Kosten invalider Hinweisreize bei Aufmerksamkeitslenkung durch endogene Hinweisreize, nicht aber bei exogenen Hinweisreizen. Die P1 und N1 Komponenten zeigten sich unbeeinflusst von Nikotin, damit findet also die Annahme einer Wirkung auf sensorische Suppression keine Unterstützung. In Experiment 3 und 4 wurde untersucht, ob Nikotin einen Effekt auf kostenträchtige unwillkürliche Aufmerksamkeitsverschiebungen, Distraktionen, hat. In Experiment 3 wurden in einem räumlichen Daueraufmerksamkeitsparadigma Distraktionen durch deviante Stimulusmerkmale ausgelöst und die Wirkung von Nikotin auf eine distraktionsassoziierte Komponente des EKP, die P3a, betrachtet. <br>In Experiment 4 wurde in einem Hinweisreizparadigma durch zusätzliche Stimuli eine Distraktion ausgelöst und die Nikotinwirkung auf die Reaktionszeitkosten untersucht. Nikotin zeigte keinen Einfluss auf Distraktionskosten in beiden Studien und auch keine Wirkung auf die P3a Komponente in Experiment 3. In Experiment 4 wurde zusätzlich die Wirkung von Nikotin auf das Loslösen von Aufmerksamkeit untersucht, indem die Schwierigkeit des Loslösens variiert wurde. Auch hier zeigte sich keine Nikotinwirkung. Allerdings konnte in beiden Studien weder die häufig berichtete generelle Reaktionszeitverkürzung noch die Verringerung der Kosten invalider Hinweisreize repliziert werden, so dass zum Einen keine Aussage über die Wirkung von Nikotin auf Distraktionen oder den Aufmerksamkeitsloslöseprozess gemacht werden können, zum Anderen sich die Frage stellte, unter welchen Bedingungen Nikotin einen differentiellen Effekt überhaupt zeigt.<br><br> Im letzten Experiment wurde hierzu die Häufigkeit der Reaktionsanforderung einerseits und die zeitlichen Aspekte der Aufmerksamkeitslenkung andererseits variiert und der Effekt des Nikotins auf den Validitätseffekt, die Reaktionszeitdifferenz zwischen valide und invalide vorhergesagten Zielreizen, betrachtet. Nikotin verringerte bei Individuen, bei denen Aufmerksamkeitslenkung in allen Bedingungen evident war, in der Tendenz den Validitätseffekt in der ereignisärmsten Bedingung, wenn nur selten willentliche Aufmerksamkeitsausrichtung notwendig war. Dies könnte als Hinweis gedeutet werden, dass Nikotin unter Bedingungen, die große Anforderungen an die Vigilanz stellen, die top-down Zuweisung von Aufmerksamkeitsressourcen unterstützt. / Nicotine has consistently been shown to improve performance on a range of attentional tasks. In spatial cueing (Posner-type) paradigms, where a cue indicates the likely location of a subsequent target stimulus, nicotine influences the ability to react to invalidly cued targets across different species and ways of administration. Previous research suggested that the cholinergic effect is due to a facilitated disengagemant of attention from the cued location. In five studies with nonsmoking subjects, three candidate mechanisms of nicotinic action were examined. <br><br> Experiment 1 and experiment 2 investigated whether nicotine modulates attentional processes of sensory gain control. In a Posner-paradigm event-related potentials (ERP) were measured and the effect of nicotine on the attention-related components P1 and N1 was assessed. Behaviorally, nicotine reduced the costs of invalid cueing when cues were endogenous, but not with exogenous cues. Electrophysiologically, the P1 and N1 components were not affected by nicotine. These data provide therefore no support for the notion of a nicotine-modulated attentional suppression. <br><br> In experiment 3 and 4 the effect of nicotine on involuntary distracting attention shifts was investigated. In experiment 3 ERPs were measured in a spatial sustained attention paradigm, where rare changes in a target stimulus attribute were used as distractors. The effect of nicotine on the distraction-associated P3a component was assessed. In experiment 4 the effect of nicotine on the reaction time costs of additional distracting stimuli was studied in a Posner paradigm. In both studies nicotine did not show an effect on distractions, neither in the reaction time costs nor in the parameters of the P3a component. Experiment 4 also investigated whether nicotine has an effect on the disengagement of attention by varying the difficulty of disengaging one's focus from the cued location. Again, nicotine did not show an effect. However, experiment 3 and 4 also neither replicated the commonly reported general nicotinic reduction of reaction times nor the differential reduction of the costs of invalid cueing. Therefore, regarding the effect of nicotine on distraction and on the disengagement of attention the data remain inconclusive. However, these data suggest that there are conditions and mechanisms moderating nicotinic action, that are still unknown. <br><br> Accordingly, experiment 5 made the attempt to determine such conditions. Response frequency and temporal characteristics of attention orientation were varied. In individuals, who evidently had shifted their attention, nicotine reduced the validity effect under uneventful conditions, when attention was not to be shifted in each trial. This might suggest that nicotine facilitates the top-down allocation of attentional resources in vigilance-demanding situations.

Conselho Nacional de Desenvolvimento Científico e Tecnológico / Phenolic compouds and their derivatives constitute a leading family of natural compounds. Caffeic acid (CA) and caffeic acid phenethyl ester (CAPE) are the important members of phenolic compound, sharing several biological applications; antioxidant, neuroprotective, anti-inflammatory, antiproliferative, antibacterial, antiviral, antiatherosclerotic and anticancer properties. In spite of these, literature reportes some of its pro-oxidants activity depending on cellular environment. These pathophysiolocal properties increased the interest to evaluate the effect of CA and CAPE on the enzyme evolved in the purines salvage and the acetylcholine hydrolyzing enzyme the acetylcholineterase (AChE); in both PNS and CNS, since the essential constituent of our dietary items. Previously, our research group has reported that phenolic compound altered the activities of these enzymes. The AChE rapidly hydrolyzes the acetylcholine in neuronal and non neuronal tissues, mediating several neurodegenerative diseases. Beside the ACh, ATP (as co-neurotramittors) and adenosine are important signaling molecules, communicating cells in both PNS and CNS. In the extracellular signalling pathways; the adenine nucleotides, their derivative and the coupling of these molecules with specific receptor have a crucial role in nervous, vascular and immune systems. Once released, these molecules are hydrolyzed by a cascade of enzymes including ectonucleoside triphosphate diphosphohydrolase (NTPDase; E.C. 3.6.1.5, CD39), 5 -nucleotidase (E.C 3.1.3.5, CD73), ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP), modulating crucially the signaling pathways in the normal functioning of nervous, vascular and immune systems. Next, adenosine deaminase (ADA) and xanthin oxidase (XO) degrade the adenosine and xanthine respectively which further control the functioning mechanisms in cellular events. Found in the neuronal and non neuronal (in both PNS and CNS) the AChE, NTPDase, 5'-nucleotidase, E-NPP, and ADA regulate several events including neurotransmission, inflammation, and thrombogenic process. We hypothesized to evaluate first the in vitro effects of CA on AChE activity in peripheral and central cholinergic system of rats. The results showed that CA significantly modulated the cholinergic system in vitro. By modulating the cholinergic system in vitro, apparently CA (e.g. phenolic structure) has proper role in neurotransmission. Therefore we hypothesizes to evaluate the in vivo effects of CA on AChE, NTPDase, E-NPP, 5'-nucleotidase, platelets aggregation and (ADA) in different tissues/cell from rats. The animals were treated during 30 days and killed after behavioral test. The results showed that caffeic acid increased significantly the AChE activity in hippocampus, hyphothalmus, pon and lymphocytes while that in cortex, cerebellum and striatum the AChE was inhibited. CA improves step-down latencies in the inhibitory avoidance. Investigating the in vivo effects of CA in purinergic system, caffecid acid increased the ATP and AMP hydrolysis in synaptosomes. However, in the synaptosomes no alterations were observed in the ADA activity in the groups evaluated in this study. CA increased the ATP and AMP hydrolysis, while the ADP hydrolysis was decreased in platelets. In the present findings caffeic acid decreased the platelets aggregation induced by ADP agonist. Treatment with CA also increased the NTPDase and ADA activities in lymphocytes of rats. Considering the dual function of caffeic acid in vitro and in vivo, the present study was extended to CAPE followed by acute treatment model (ip) in order to elucidate the effect of another phenolic structure on the same parameters. In this line the animals were treated (ip) with CAPE and killed after 40 minutes. In platelets, the results showed that the effect of CAPE increased the NTPDase, E-NPP, 5 -nucleotidase activities, while ADA activities did not change significantly. In synaptosomes CAPE significantly inhibited the NTPDase, and 5 -nucleotidase activity. CAPE induced no significant changes in ADA in synaptosomes but reduced XO in whole brain. Finaly we investigated the activity of AChE in cortex, cerebellum, striatum, hippocampus, hyphotalamus, pon, lymphocytes and muscules of rats treated with CAPE. The results showed that CAPE significantly decreased the AChE activity in cortex cerebellum and striatum. CAPE significantly increased the AChE activity in hippocampus hypothalamus, pons, muscle and lymphocytes. In cholinergic system our results clearly demonstrating that both compound with dual functions.These findings demonstrated that the AChE activities and the cascade of ecto-enzymes was alter in different tissues after treatment with CA and CAPE in rats, suggesting that these compound should be considered a potentially therapeutic agent in immune, vascular and neurological disorders related with the cholinergic purinergic system. / Os compostos fenólicos e seus derivados constituem uma importante família de compostos naturais. O ácido cafeico (AC) e o éster fenetil do ácido cafeico (CAPE) são membros importantes dessa família e compartilham algumas aplicações biológicas, tais como: antioxidante, neuroprotetor, antiinflamatório, antiproliferativo, antibacteriano, antiviral, antiaterosclerótico e anticancerígeno. Entretanto, a literatura relata algumas atividades pró-oxidantes, dependendo do ambiente celular. Devido a estas propriedades patofisiológicas, aumentou o interesse com o objetivo de avaliar o efeito de CA e CAPE sob as atividades das enzimas purinérgicas e da acetilcolinesterase (AChE), tanto no Sistema Nervoso Periférico (SNP) como no Sistema Nervoso Central (SNC). Previamente, nosso grupo de pesquisa relatou que o composto fenólico tem a capacidade de alterar as atividades dessas enzimas. A AChE rapidamente hidrolisa a acetilcolina (ACh) em tecidos neuronais e não neuronais, mediando algumas doenças neurodegenerativas. Ao lado da ACh, o ATP (como coneurotransmissor) e adenosina são importantes moléculas sinalizadoras, comunicando as células em ambos os SNP e do SNC. Nas vias de sinalização extracelulares, os nucleotídeos de adenina e seus derivados podem ser acoplados a receptores específicos e desse modo ter um papel crucial no sistema nervoso, sistema vascular e imune. Uma vez liberadas, estas moléculas são hidrolisadas por uma cascata de enzimas incluindo a ectonucleosídeo trifosfato difosfoidrolase (NTPDase; EC 3.6.1.5, CD39), 5'- nucleotidase (EC 3.1.3.5, CD73), ectonucleotideo pirofosfatase/fosfodiesterase (E-NPP), modulando definitivamente as vias de sinalização do funcionamento normal do sistema nervoso, sistema vascular e imune. Além disso, a adenosina deaminase (ADA) e a xantina oxidase (XO) degradam a adenosina e a xantina, respectivamente, as quais controlam o funcionamento de mecanismos em eventos celulares. As enzimas encontradas em tecidos neuronais e não neuronais como a AChE, a NTPDase, a 5'-nucleotidase, a E-NPP e a ADA regulam eventos celulares incluindo a neurotransmissão, inflamação e processos trombogênicos. Com essas informações, nós introduzimos a hipótese de avaliar primeiramente os efeitos in vitro de CA na atividade da AChE periférica e no sistema central colinérgico de ratos. Os resultados demonstraram que o CA modula significativamente o sistema colinérgico no estudo in vitro. Essa modulação demonstra aparentemente que o CA (estrutura fenólica) possui propriedades de ação que altera a neurotransmissão. Portanto, a hipótese de se avaliar os efeitos in vivo de CA na atividade da AChE, NTPDase, E-NPP, 5'-nucleotidase, ADA e da agregação de plaquetas em diferentes tecidos de ratos tornou-se evidente. Para esse estudo, os animais foram tratados durante 30 dias e sacrificados após o teste comportamental. Os resultados do experimento demonstraram que o CA aumentou significativamente a atividade da AChE em hipocampo, hipotálamo, ponte e nos linfócitos, enquanto que no córtex cerebral, cerebelo e estriado a AChE foi inibida. No teste comportamental o CA teve evolução de melhora na latência de passos da esquiva inibitória. A investigação dos efeitos in vivo do CA no sistema purinérgico demonstrou aumento na hidrólise de ATP e AMP em sinaptossomas. Entretanto, não foram observadas alterações significativas na atividade da ADA em sinaptossomas dos grupos avaliados neste estudo. Em plaquetas, o CA aumentou significativamente a hidrólise de ATP e AMP, enquanto que a hidrólise de ADP foi diminuída nesse tecido. No presente estudo o CA reduziu significativamente a agregação de plaquetas induzida pelo agonista ADP. Além disso, o tratamento com CA aumentou significativamente as atividades da NTPDase e da ADA em linfócitos de ratos. Considerando a dupla função de CA, in vitro e in vivo, o presente estudo foi estendido para CAPE seguindo o modelo de tratamento agudo pela via intraperitoneal (ip) com o objetivo de elucidar o efeito de uma segunda estrutura fenólica sobre os mesmos parâmetros. Nesta linha de pesquisa, os animais foram tratados ip com CAPE e eutanasiados após 40 minutos. Em plaquetas, os resultados demonstraram que o CAPE aumentou significativamente a atividade da NTPDase, E-NPP e 5'-nucleotidase, enquanto que a atividade da ADA não foi alterada significativamente. Em sinaptossomas, o CAPE inibiu significativamente a atividade da NTPDase e da 5'-nucleotidase. O CAPE não induziu alterações significativas na atividade da ADA em sinaptossomas, mas reduziu significativamente a atividade da XO em todo o cérebro. Finalmente, nós investigamos a atividade da AChE no córtex cerebral, cerebelo, estriado, hipocampo, hipotálamo, ponte, linfócitos e músculos de ratos tratados com CAPE. Os resultados demonstraram que CAPE diminuiu significativamente a atividade da AChE em córtex cerebral, cerebelo e estriado. O CAPE aumentou significativamente a atividade da AChE em hipotálamo, hipocampo, ponte, músculo e linfócitos. No sistema colinérgico, nossos resultados demonstram claramente que ambos os compostos possuem dupla função. Estes resultados demonstram que as atividades da AChE e da cascata das ecto-enzimas foram alteradas em diferentes tecidos após o tratamento com CA ou CAPE em ratos, sugerindo que estes compostos devem ser considerados agentes com potencial terapêutico em doenças imunes, vasculares e neurológicas relacionadas com o sistema colinérgico e purinérgico.